Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
Heras-Murillo I. et al, (2025), Nature Communications, 16
Barriers to publishing early phase clinical trials: the oncologists’ perspective
Lucassen MJJ. et al, (2025), The Oncologist, 30
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors.
de Bono JS. et al, (2025), Clinical cancer research : an official journal of the American Association for Cancer Research
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Melero I. et al, (2025), Nature
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models
Garate-Soraluze E. et al, (2025), Journal for ImmunoTherapy of Cancer, 13, e009852 - e009852
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.
Ascierto PA. et al, (2025), Journal for immunotherapy of cancer, 13
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
Melero I. et al, (2025), Nature, 637, 1218 - 1227
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Lopez J. et al, (2025), Nature Medicine, 31, 152 - 164
Cross-priming in cancer immunology and immunotherapy.
Luri-Rey C. et al, (2025), Nature reviews. Cancer
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma
Solórzano JL. et al, (2024), OncoImmunology, 13
Regional and intratumoral adoptive T-cell therapy
Olivera I. et al, (2024), Immuno-Oncology and Technology, 24, 100715 - 100715
Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines
Berraondo P. et al, (2024), Cancer Discovery, 14, 2021 - 2024
Targeting T-cell costimulation to the surface of tumor cells.
Eguren-Santamaría I. et al, (2024), Clinical cancer research : an official journal of the American Association for Cancer Research
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
Ascierto PA. et al, (2024), NEJM Evidence, 3
Transcriptional and hormonal profiling uncovers the interactions between plant developmental stages and RNA virus infection
Melero I. et al, (2024), Journal of General Virology, 105
CD137 (4-1BB) and T-Lymphocyte Exhaustion
Molero-Glez P. et al, (2024), Clinical Cancer Research, 30, 3971 - 3973
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
Eguren-Santamaria I. et al, (2024), Journal for immunotherapy of cancer, 12
Reply to the Letter to the Editor “Reflections on the statistical methodology in nivolumab and ipilimumab therapy research” by S. Yang
Melero I. et al, (2024), Annals of Oncology, 35, 827 - 828
Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy
Martínez-Riaño A. et al, (2024), Clinical Cancer Research, 30, 3355 - 3357